Ozanezumab

Drug Profile

Ozanezumab

Alternative Names: 1223249; GSK1223249

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Monoclonal antibodies
  • Mechanism of Action Nogo protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Multiple sclerosis

Most Recent Events

  • 01 Jan 2015 GlaxoSmithKline completed a phase II trial in Amyotrophic lateral sclerosis in USA, Australia, Belgium, Canada, France, Germany, Italy, Japan, South Korea and Netherlands and United Kingdom (NCT01753076)
  • 13 Feb 2014 GlaxoSmithKline completes enrolment in its phase II trial for Amyotrophic lateral sclerosis in USA, Canada, European Union, Australia, Japan & South Korea (NCT01753076)
  • 31 Dec 2013 Phase-II clinical trials in Amyotrophic lateral sclerosis in USA, Japan & South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top